| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PAK5 |
| Uniprot No | Q8TB93 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-293aa |
| 氨基酸序列 | MFGKKKKKIEISGPSNFEHRVHTGFDAQEQKFTGLPQQWHSLLADTANRPKPMVDPSCITPIQLAPMKTIVRGNKPCKETSINGLLEDFDNISVTRSNSLRKESPPTPDQGASSHGPGHAEENGFITFSQYSSESDTTADYTTEKYREKSLYGDDLDPYYRGSHAAKQNGHVMKMKHGEAYYSEVKPLKSDFARFSADYHSHLDSLSKPSEYSDLKWEYQRASSSSPLDYSFQFTPSRTAGTSGCSKESLAYSESEWGPSLDDYDRRPKSSYLNQTSPQPTMRQRSRSGSGLQ |
| 预测分子量 | 34.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PAK5重组蛋白的3篇示例参考文献(注：文献为示例性概括，实际研究请通过学术数据库查询)：
---
1. **文献名称**：*"Expression and Functional Characterization of Recombinant PAK5 in Cancer Cell Motility"*
**作者**：Zhang Y, et al.
**摘要**：该研究通过在大肠杆菌中表达并纯化重组PAK5蛋白，验证了其激酶活性，并发现其在体外能显著增强癌细胞的迁移能力，提示PAK5可能通过调控细胞骨架重塑促进肿瘤转移。
2. **文献名称**：*"Structural Insights into PAK5 Activation Using Recombinant Protein Technology"*
**作者**：Lee S, Kim JH.
**摘要**：通过重组PAK5的晶体结构解析，揭示了其自抑制构象及Cdc42结合后的激活机制，为设计靶向PAK5的小分子抑制剂提供了结构基础。
3. **文献名称**：*"Recombinant PAK5 Modulates Apoptosis in Neuronal Cells via Mitochondrial Pathways"*
**作者**：Wang X, et al.
**摘要**：研究利用哺乳动物细胞表达系统制备重组PAK5.证明其过表达可抑制神经元凋亡，并阐明其通过Bcl-2家族蛋白调控线粒体途径的作用机制。
---
如需真实文献，建议在PubMed或Web of Science中检索关键词“PAK5 recombinant protein”或“PAK5 expression and function”。
PAK5 (p21-activated kinase 5) is a member of the PAK family of serine/threonine kinases, which play critical roles in regulating cytoskeletal dynamics, cell survival, proliferation, and migration. Unlike other PAK isoforms (Group I: PAK1-3; Group II: PAK4-6), PAK5 is predominantly expressed in the brain and nervous system, suggesting specialized functions in neuronal development and synaptic plasticity. It is activated by binding to small GTPases Cdc42 and Rac1. triggering downstream signaling cascades involving MAPK, Wnt/β-catenin, and PI3K/Akt pathways. PAK5 has garnered attention for its dual roles in both promoting cell survival and apoptosis, depending on cellular context and stress signals.
Recombinant PAK5 protein is engineered using expression systems (e.g., E. coli, mammalian cells) to produce purified, functional kinase for research applications. Its recombinant form enables studies on enzymatic activity, substrate interactions, and drug discovery targeting PAK5-associated diseases. Dysregulation of PAK5 is implicated in neurological disorders (e.g., Alzheimer’s disease, schizophrenia) and cancers, where it often exhibits aberrant overexpression linked to tumor invasion and chemoresistance. For example, PAK5 promotes epithelial-mesenchymal transition (EMT) in cancer by phosphorylating β-catenin, enhancing its nuclear translocation.
Researchers utilize recombinant PAK5 to screen inhibitors, map signaling networks, and explore its crosstalk with neurodegenerative pathways. Its unique tissue distribution and structural features (e.g., a C-terminal kinase domain and an N-terminal regulatory domain) make it a distinct therapeutic target. However, challenges remain in understanding isoform-specific functions and optimizing selective modulators. Ongoing studies aim to clarify PAK5’s role in mitochondrial dynamics, autophagy, and synaptic signaling, highlighting its potential as a biomarker or therapeutic candidate in precision medicine.
×
